Patents by Inventor Peter J. Langecker

Peter J. Langecker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
    Publication number: 20030191162
    Abstract: The present invention relates to 3-heteroarylidenyl-2-indolinone compounds that modulate the enzymatic activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. Furthermore, these compounds are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer.
    Type: Application
    Filed: December 2, 2002
    Publication date: October 9, 2003
    Applicant: Sugen Inc.
    Inventors: Peter J. Langecker, Laura K. Shawyer, Peng Cho Tang, Li Sun, Alison Lennox Hannah, David Kevin Kwok
  • 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY
    Publication number: 20030073837
    Abstract: The present invention relates to 3-heteroarylidenyl-2-indolinone compounds that modulate the enzymatic activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. Furthermore, these compounds are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer.
    Type: Application
    Filed: December 30, 1999
    Publication date: April 17, 2003
    Inventors: PETER J. LANGECKER, LAURA K. SHAWVER, PENG CHO TANG, LI SUN
  • Combination therapy for the treatment of estrogen-sensitive disease
    Publication number: 20020119502
    Abstract: The present invention provides methods which increase the effectiveness of combination drug therapies for treating estrogen-sensitive diseases, such as breast cancer, as well as novel combinations useful to treat such diseases.
    Type: Application
    Filed: October 3, 2001
    Publication date: August 29, 2002
    Inventors: Mark Stanford Moran, Peter J. Langecker